Autres langues Cerevel Therapeutics Holdings, Inc.

Actions

CERE

US15678U1280

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
42,12 ^USD	+0,51 %		-0,06 %	-0,67 %

18/04	Le médicament de Cerevel Therapeutics contre la maladie de Parkinson atteint l'objectif principal d'une étude de stade avancé	RE
18/04	Cerevel Therapeutics annonce des résultats positifs pour le tavapadon dans l'étude de phase 3 adjuvante pour les personnes atteintes de la maladie de Parkinson	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	19/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	18/04
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	18/04
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	18/04
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	18/04
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	18/04
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25/03
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	04/03
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Sector Update: Health Care Stocks Gain Late Afternoon	22/02
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	22/02
Phew! The party continues!	22/02
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	22/02
North American Morning Briefing : Stock Futures -2-	21/02
AbbVie CEO to Retire; COO Robert Michael Named Successor	20/02
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	13/02
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	12/02
AbbVie 4Q Sales Lower as Himura Revenue Sinks	02/02
Omzetdaling Abbvie valt mee	02/02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cerevel Therapeutics Holdings, Inc.

Actions

CERE

US15678U1280

Autres langues

Filtres